我們已在上線! 進一步了解
BIO圖示

Bio-Rad Laboratories Class A

353.70 USD
-11.12
3.05%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
353.70
0.00
0%
1天
-3.05%
5天
-4.37%
1個月
-6.68%
3個月
17.52%
6個月
21.51%
今年迄今
15.86%
1年
13.22%
5年
-51.36%
10年
119.16%
 

關於: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

員工: 7,450

新聞

正面
中性
負面
市場情緒 3個月
正面 33.3%
中性 55.6%
負面 11.1%
中性
Business Wire
前天
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the.
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
正面
MarketBeat
21 天前
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions.
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
中性
Seeking Alpha
22 天前
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
負面
Zacks Investment Research
23 天前
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
中性
Business Wire
上個月
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relation.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
正面
Seeking Alpha
上個月
Bio-Rad: Favorable Read-Across From Investor Event
Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.
Bio-Rad: Favorable Read-Across From Investor Event
中性
Seeking Alpha
上個月
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
正面
Zacks Investment Research
上個月
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
中性
Business Wire
上個月
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
正面
Zacks Investment Research
上個月
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
價格圖表採用Lightweight Charts™實作